Bank Julius Baer & Co. Ltd, Zurich Infla Rx N.V. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$1.83 - $4.48 $361,620 - $885,279	-197,607 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$2.25 - $3.03 $81 - $109	-36 Reduced 0.02%	197,607 $512,000
Q2 2021 Jul 23, 2021	BUY	$2.72 - $4.04 $537,588 - $798,477	197,643 New	197,643 $587,000
Q1 2021 May 10, 2021	SELL	$3.62 - $6.34 $715,362 - $1.25 Million	-197,614 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$3.82 - $5.32 $26 - $37	7 Added 0.0%	197,614 $994,000
Q4 2020 Feb 12, 2021	BUY	$3.82 - $5.32 $754,858 - $1.05 Million	197,607 New	197,607 $994,000

13.2M

5.2K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $67.6M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.